Odyssey Health (OTCPK:ODYY) - Stock Price, News & Analysis

ODYY Stock Overview

A medical company, focuses on the development and commercialization of medical products.

ODYY fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	3/6
Financial Health	3/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (0.3x) is below the US market (18.1x)

Became profitable this year

Risk Analysis

Does not have a meaningful market cap ($3M)

Highly volatile share price over the past 3 months

Makes less than USD$1m in revenue ($0)

Large one-off items impacting financial results

+ 1 more risk

Odyssey Health, Inc. Competitors

Rayont

OTCPK:RAYT

US$4.6m

Daxor

NasdaqCM:DXR

US$46.4m

Vaso

OTCPK:VASO

US$41.3m

Pro-Dex

NasdaqCM:PDEX

US$83.1m

Price History & Performance

Summary of all time highs, changes and price drops for Odyssey Health
Historical stock prices
Current Share Price	US$0.031
52 Week High	US$0.23
52 Week Low	US$0.021
Beta	-0.66
11 Month Change	-20.03%
3 Month Change	-36.99%
1 Year Change	-66.00%
33 Year Change	-90.33%
5 Year Change	-97.67%
Change since IPO	-87.42%

Recent updates

Shareholder Returns

	ODYY	US Medical Equipment	US Market
7D	4.8%	0.4%	3.0%
1Y	-66.0%	17.1%	25.3%

Return vs Industry: ODYY underperformed the US Medical Equipment industry which returned 17.1% over the past year.

Return vs Market: ODYY underperformed the US Market which returned 25.3% over the past year.

Price Volatility

Is ODYY's price volatile compared to industry and market?
ODYY volatility
ODYY Average Weekly Movement	40.6%
Medical Equipment Industry Average Movement	8.6%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ODYY's share price has been volatile over the past 3 months.

Volatility Over Time: ODYY's weekly volatility has increased from 34% to 41% over the past year.

About the Company

Founded	Employees	CEO	Website
2014	6	n/a	www.odysseyhealthinc.com

Odyssey Health, Inc., a medical company, focuses on the development and commercialization of medical products. It develops CardioMap, a heart monitoring and screening device; Save A Life choking rescue devices; and ONP -001 and ONP -002 neurosteroid drug compounds to treat concussions and rare brain disorders. The company was formerly known as Odyssey Group International, Inc. Odyssey Health, Inc. was incorporated in 2014 and is based in Las Vegas, Nevada.

Odyssey Health, Inc. Fundamentals Summary

How do Odyssey Health's earnings and revenue compare to its market cap?
ODYY fundamental statistics
Market cap	US$3.38m
Earnings (TTM)	US$11.02m
Revenue (TTM)	n/a

0.3x

P/E Ratio

0.0x

P/S Ratio

Is ODYY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ODYY income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	-US$11.02m
Earnings	US$11.02m

Last Reported Earnings

Apr 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.11
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	20.3%

How did ODYY perform over the long term?

See historical performance and comparison

ODYY Stock Overview

Rewards

Risk Analysis

Odyssey Health, Inc. Competitors

OTCPK:RAYT

US$4.6m

NasdaqCM:DXR

US$46.4m

OTCPK:VASO

US$41.3m

NasdaqCM:PDEX

US$83.1m

Price History & Performance

Recent News & Updates

Odyssey Health, Inc. announced that it has received $0.3 million in funding

Odyssey Health, Inc. announced delayed 10-Q filing

Oragenics, Inc. (NYSEAM:OGEN) completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Oragenics, Inc. (NYSEAM:OGEN) entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Odyssey Health, Inc. Presents Concussion Treatment Data At the Military Health System Research Symposium -MHSRS

Odyssey Health, Inc. (OTCPK:ODYY) executed a non- binding letter of intent to acquire Speranza Therapeutics, Inc.

Recent updates

Odyssey Health, Inc. announced that it has received $0.3 million in funding

Odyssey Health, Inc. announced delayed 10-Q filing

Oragenics, Inc. (NYSEAM:OGEN) completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Oragenics, Inc. (NYSEAM:OGEN) entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Odyssey Health, Inc. Presents Concussion Treatment Data At the Military Health System Research Symposium -MHSRS

Odyssey Health, Inc. (OTCPK:ODYY) executed a non- binding letter of intent to acquire Speranza Therapeutics, Inc.

Odyssey Health, Inc. Appoints Jeffrey Conroy as Director

Odyssey Health, Inc. to Develop Intranasal Field- Deliverable Nerve Agent Antidote

Odyssey Health, Inc. Announces Resignation of Jeffrey Conroy as Director

Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development

Odyssey Health, Inc., Annual General Meeting, Jan 12, 2023

Odyssey Health Inc. Announces Expansion of Executive Team

Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device

Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug

Odyssey Health, Inc. Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial, Cohort II

Odyssey Health, Inc. Announces the Successful Completion of Safety Measures for Their Phase I Multi-Day Ascending Dosing (Mad) Clinical Trial

Odyssey Health, Inc. Announces Positive Results from its Phase I Multi-Day Ascending Dosing for the Treatment of Concussion

Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug

Odyssey Health, Inc. Completes Safety Evaluation of Cohort I for Concussion Drug

Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug

Odyssey Health, Inc. Names Vice Admiral (r) Timothy Szymanski to the Military Advisory Board

Odyssey Group International Announces Formation of Military Advisory Board

Odyssey Group International, Inc. Continues Enrollment of its First in Kind Human Clinical Trial of its Proprietary Drug Compound Intended to Treat Concussion

Odyssey Group International, Inc. Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion

Odyssey Group International, Inc. Approves to Start Human Trial to Treat Concussion

Odyssey Group International Completes IND-enabling Studies, Submits Investigator’s Brochure for Phase 1 Clinical Trial

Odyssey Group International Reports Achieving Drug Safety Standards for Clinical Trials of its Drug for Treating Concussion

Odyssey Group International, Inc. announced delayed 10-Q filing

Odyssey Group International Announces Successful Completion of Their Novel Nano-Particle Drug Formulation for Treating Concussion

Odyssey Group International, Inc. Announces the Completion of the Food and Drug Administration (FDA) Required Toxicology Studies Designed to Support Clinical Trials with Prv-002

Odyssey Group International Announces Completion of Novel Device for Nasal Delivery of Concussion Drug Candidate

Odyssey Group International, Inc. announced a financing transaction

Odyssey Group International, Inc. announced delayed annual 10-K filing

Odyssey Group International, Inc. announced that it expects to receive $10.6 million in funding from The EquiLux Group, LP, Lincoln Park Capital, LLC